01:09a | JOHNSON & JOHNSON : Some Key Questions Answered On Covid-19 Vaccines for African.. | AQ |
01/18 | JOHNSON & JOHNSON : - DARZALEX FASPRO Becomes the First FDA-Approved Treatment f.. | AQ |
01/17 | FAUCI : U.S. 'weeks away' from evaluating new vaccine candidates | AQ |
01/15 | JOHNSON & JOHNSON : DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Become.. | PU |
01/15 | "MY 2021 HEALTHCARE RESOLUTION" : 7 Johnson & Johnson Leaders Share Their Goals .. | PU |
01/14 | JOHNSON & JOHNSON : Statement on Political Contributions | PU |
01/14 | NEXTECH AR : sees $7.3M in business for Q4 | AQ |
01/14 | Presidency On Africa Centres for Disease Control and Prevention Securing Firs.. | AQ |
01/14 | THE COVID-19 DATA PLAN : 3 Innovative Ways Johnson & Johnson Is Using Data Scien.. | AQ |
01/14 | 270 Million Covid-19 Vaccine Doses Secured for Africa | AQ |
01/13 | JOHNSON & JOHNSON : COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published.. | PU |
01/13 | JOHNSON & JOHNSON : African Union buys 270 million vaccine doses for continent | AQ |
01/13 | JOHNSON & JOHNSON : Janssen to Highlight Commitment to Lung Cancer Science and I.. | AQ |
01/12 | JOHNSON & JOHNSON : Janssen to Highlight Commitment to Lung Cancer Science and I.. | PU |
01/09 | The Cold Supply Chain Can't Reach Everywhere - That's a Big Problem for Equit.. | AQ |
01/08 | COVID-19 UPDATE : Your Latest Questions About Johnson & Johnson's Investigationa.. | AQ |
01/07 | The Vaccine Cold Supply Chain Can't Reach Everywhere | AQ |
01/07 | JOHNSON & JOHNSON : Statement by Alex Gorsky Johnson & Johnson Chairman and CEO | AQ |
01/04 | JOHNSON & JOHNSON : Announces Quarterly Dividend for First Quarter 2021 | PR |
2020 | JOHNSON & JOHNSON : Janssen Submits European Marketing Authorisation Application.. | AQ |
2020 | JOHNSON & JOHNSON : Disease-Free Survival Data from CAPTIVATE Study Demonstrate .. | PU |
2020 | JOHNSON & JOHNSON : Updated Results from the Phase 1 Study of the BCMAxCD3 Bispe.. | PU |
2020 | JOHNSON & JOHNSON : Early, Deep, Durable Responses of Ciltacabtagene Autoleucel .. | PU |
2020 | JOHNSON & JOHNSON : to Participate in the 39th Annual J.P. Morgan Healthcare Con.. | PU |
2020 | JOHNSON & JOHNSON : New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibruti.. | PU |
2020 | JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking Approval of .. | PU |
2020 | BIOSTOCK : Iconovo address maternal health in partnership with Monash University | AQ |
2020 | JOHNSON & JOHNSON : Janssen Initiates Rolling Submission of a Biologics License .. | AQ |
2020 | JOHNSON & JOHNSON : Announces Agreement in Principle with Gavi to Supply Janssen.. | AQ |
2020 | JOHNSON & JOHNSON : to Host Investor Conference Call on Fourth-Quarter Results | AQ |
2020 | JOHNSON & JOHNSON : Janssen Initiates Rolling Submission of a Biologics License .. | PU |
2020 | ICONOVO : signs agreement for development of inhaled oxytocin in ICOone for mate.. | AQ |
2020 | JOHNSON & JOHNSON : Changing "Date Of Status" And "First Reported Date" May Expo.. | AQ |
2020 | JOHNSON & JOHNSON : WHO's COVID-19 vaccine drive doubles global supply to 2 bill.. | AQ |
2020 | JOHNSON & JOHNSON : to Host Investor Conference Call on Fourth-Quarter Results | PU |
2020 | JOHNSON & JOHNSON : Announces Its First Phase 3 COVID-19 Vaccine Trial ENSEMBLE .. | AQ |
2020 | JOHNSON & JOHNSON : Conference Chair from Johnson & Johnson Invites You to Atten.. | AQ |
2020 | JOHNSON & JOHNSON : Dow Jones, S&P 500 and Nasdaq Composite all hit record highs.. | AQ |
2020 | JOHNSON & JOHNSON : IP Rights Will Reduce Health Burden, Improve Economy, Expert.. | AQ |
2020 | XBRANE BIOPHARMA : Nina Ivers joins Xbrane Biopharma as Head of HR | AQ |
2020 | JOHNSON & JOHNSON : to Participate in the 39th Annual J.P. Morgan Healthcare Con.. | PU |
2020 | OKLAHOMA ASKS COURT : Make J&J pay $9.3B to end opioid crisis | AQ |
2020 | "WHAT IT'S LIKE TO BE IN A CLINICAL : 3 People Share Their Personal Stories | PU |
2020 | JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - New Data Demonstrate Long.. | AQ |
2020 | South Korea to begin COVID-19 vaccinations by March | AQ |
2020 | JOHNSON & JOHNSON : - DARZALEX Data Show Deeper and Longer Responses in Patients.. | AQ |
2020 | JOHNSON & JOHNSON : - Data from the ANDROMEDA Study Show Hematologic Response fo.. | AQ |
2020 | JOHNSON & JOHNSON : Data from the ANDROMEDA Study Show Hematologic Response for .. | PU |
2020 | JOHNSON & JOHNSON : Data from the APOLLO Study Show Clinically Meaningful Respon.. | PU |
2020 | JOHNSON & JOHNSON : New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibruti.. | PU |
2020 | JOHNSON & JOHNSON : Janssen Presents First Data from the Phase 1 Study of the GP.. | PU |
2020 | JOHNSON & JOHNSON : Updated Results from the Phase 1 Study of the BCMAxCD3 Bispe.. | PU |
2020 | JOHNSON & JOHNSON : Early, Deep, Durable Responses of Ciltacabtagene Autoleucel .. | PU |
2020 | JOHNSON & JOHNSON : Disease-Free Survival Data from CAPTIVATE Study Demonstrate .. | PU |
2020 | JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking Approval of .. | AQ |
2020 | IMPACT DURING A PANDEMIC : 5 Ways Johnson & Johnson Was Recognized for Its COVID.. | PU |
2020 | JOHNSON & JOHNSON : Janssen Headlines American Society of Hematology Annual Meet.. | PU |
2020 | JOHNSON & JOHNSON : Change in Directors or Principal Officers (form 8-K) | AQ |
2020 | JOHNSON & JOHNSON : Names Dr. Nadja West, retired United States Army lieutenant .. | PR |
2020 | JOHNSON & JOHNSON : Announces Fireside Chat Webcast on Janssen's Eye Disease Por.. | PU |
2020 | HOFSETH BIOCARE ASA : HBC adds ex-Johnson & Johnson Senior Commercial leader, Wi.. | AQ |
2020 | JOHNSON & JOHNSON : European Commission Approves Janssen's TREMFYA®▼ (guse.. | PU |
2020 | JOHNSON & JOHNSON : New Survey Finds Critical Need for Education on Cataracts an.. | PR |
2020 | JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - European Commission Appro.. | AQ |
2020 | JOHNSON & JOHNSON : Pfizer, and Merck Lost $3.5B in Combined YTD Revenue | AQ |
2020 | JOHNSON & JOHNSON : Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supple.. | PU |
2020 | JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse.. | PU |
2020 | JOHNSON & JOHNSON : New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) D.. | PU |
2020 | JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t.. | PU |
2020 | JOHNSON & JOHNSON : Late-Breaking 12-Month Data of Investigational RPGR Gene The.. | PU |
2020 | JOHNSON & JOHNSON : to Address Racial and Social Injustice through Platform that.. | AQ |
2020 | THE LATEST : British PM Johnson tests negative for virus | AQ |
2020 | THE LATEST : British PM Johnson tests negative for virus | AQ |
2020 | JOHNSON & JOHNSON : Southampton Professor to lead Janssen COVID-19 vaccine trial | AQ |
2020 | JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse.. | AQ |